22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
Under the title “New York May Soon Increase Recoverable Wrongful Death Damages,” we wrote recently...
Read More >
In yet another development in the closely watched case of Rizo v. Yovino, the en banc Ninth Circuit ...
Read More >
Washington Nationals Stay in the Fight. The Washington Nationals are heading to the World Series for...
Read More >
Employers with employees in Ontario often ask about legislative requirements under various employmen...
Read More >
Seyfarth Synopsis: Many of the limitations that apply to tax-qualified plans, including 401(k) plans...
Read More >
The Work Injury Compensation Bill 2019 (the Bill) was passed in Parliament on 3 September 2019. Broa...
Read More >